Lilly says labeling for Zyprexa and Symbyax reflects recent data

Eli Lilly & Co. says updated labeling for its atypical antipsychotics Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine HCl) reflects recently completed pooled analyses of clinical trial data in adults and adolescents, information from two non-Eli Lilly studies, and discussions with the FDA.
You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory